Coagulation Factor Market Reviewed in Most Recent Research Report Published at MarketPublishers.com25 Nov 2011 • by Natalie Aster
LONDON – Last year, global sales of the five major recombinant products of coagulation factors VIII, IX and VIIa reached USD 6.2 billion. The first marketing authorization application for a novel recombinant coagulation factor has been submitted in the EU and further novel wild-type and long-acting recombinant coagulation factors VIII, IX and VII are in advanced clinical stages with potential regulatory approvals within the next two to four years.
New research report “Coagulation Factors 2011 – Who Does Meet the Market Needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis” worked out by La Merie SL provides a description, evaluation and assessment of the recombinant coagulation factor R&D pipelines as of October 2011. The study analyzes and assesses the target pipeline for each of the coagulation factors for haemophilia and features the target profiles of development projects.
- R&D pipeline overview;
- profiles of most promising coagulation factors in the pipeline;
- pipeline analysis for each coagulation factor;
- evaluation and assessment of protein engineering and drug delivery technologies;
- overview and analysis of marketed coagulation factors;
- market research study with haematologists from haemophilia care centers;
- corporate product portfolios and R&D pipelines;
- benchmark of competitors regarding achievement of product target profiles.
Title: Coagulation Factors 2011 – Who Does Meet the Market Needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis
Published: October, 2011
Price: US$ 3,258
1 EXECUTIVE SUMMARY
3 COAGULATION FACTOR MARKETS
3.1 Recombinant Factor VIIIa Market
3.2 Recombinant Factor IXa Market
3.3 Recombinant Factor VIIa Market
3.4 Total Market Size of Recombinant Coagulation Factors for Hemophilia
3.5 Recombinant Thrombin Market
3.6 Total Market Sizes and Market Shares of Rec. Coagulation Factors
3.7 Plasma-Derived Coagulation Factors
4 PIPELINE CHANGES SINCE SEPTEMBER 2010
4.1 Alnylam Pharmaceuticals
4.2 Amsterdam Molecular Therapeutics
4.4. Bayer Healthcare Pharmaceuticals
4.5 Biogen Idec
4.6 Catalyst Biosciences
4.8 Green Cross
4.9 Grifols (Talecris Biotherapeutics)
4.10 Ipsen & Inspiration Biopharmaceuticals
4.11 LFB (GTC Biotherapeutics)
4.12 Novo Nordisk
4.16 Pfizer (Wyeth)
4.18 Prolor Biotech
4.19 PTC Therapeutics
More new research reports by the publisher can be found at La Merie SL page.
The Market Publishers, Ltd.
Tel: +44 208 144 6009
Fax: +44 207 900 3970